Systematic Review of Available CAR-T Cell Trials around the World

The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001

(2022) Esteve Trias et al.   BONE MARROW TRANSPLANTATION

Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

(2022) J. Joseph Melenhorst et al.   NATURE

CAR T cells produced in vivo to treat cardiac injury

(2022) Joel G. Rurik et al.   SCIENCE

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma

(2021) Vita Golubovskaya et al.   Cancers

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

(2021) Jesus G Berdeja et al.   LANCET

CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus

(2021) Dimitrios Mougiakakos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ

(2021) Sanjay Chandrasekaran et al.   Frontiers in Immunology

Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies?

(2021) Kevin Tang et al.   Journal of Immunotherapy and Precision Oncology

Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

(2021) Anne Mea Spanjaart et al.   LEUKEMIA

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

(2021) Michael R. Bishop et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

(2021) Frederick L. Locke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience

(2021) Beatrice Casadei et al.   Cancers

Myeloid Immune Cells CARrying a New Weapon Against Cancer

(2021) Rodrigo Nalio Ramos et al.   Frontiers in Cell and Developmental Biology

Transposon-mediated generation of CAR-T cells shows efficient anti B-cell leukemia response after ex vivo expansion

(2020) Leonardo Chicaybam et al.   GENE THERAPY

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

(2020) Enli Liu et al.   NEW ENGLAND JOURNAL OF MEDICINE

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

(2020) Michael Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia

(2020) Meir Rozenbaum et al.   Frontiers in Immunology

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

(2020) Jeremy S Abramson et al.   LANCET

HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases

(2019) Steven C. Katz et al.   CANCER GENE THERAPY

CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications

(2018) Ulrike Köhl et al.   HUMAN GENE THERAPY

Role of Bruton’s tyrosine kinase in B cells and malignancies

(2018) Simar Pal Singh et al.   Molecular Cancer

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

The B cell receptor signaling pathway in mantle cell lymphoma

(2018) Maria I. Merolle et al.   Oncotarget

CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions

(2018) Wanghong Hu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma

(2018) Najat Bouchkouj et al.   CLINICAL CANCER RESEARCH

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

A versatile system for rapid multiplex genome-edited CAR T cell generation

(2017) Jiangtao Ren et al.   Oncotarget

CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells

(2017) Yongping Zhang et al.   Frontiers of Medicine

Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model

(2016) Eloah Rabello Suarez et al.   Oncotarget

Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies

(2015) Laurent Poirot et al.   CANCER RESEARCH

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

(2015) Carla Casulo et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Engineered T cells for cancer therapy

(2014) Carl H. June et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR

(2012) H. Torikai et al.   BLOOD

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

(2011) S. E. M. Herman et al.   BLOOD

Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication

(2011) Sergio A. Quezada et al.   IMMUNOLOGICAL REVIEWS